Burkholderia gladioli: Five year experience in a cystic fibrosis and lung transplantation center  by Kennedy, Marcus P. et al.
6 (2007) 267–273
www.elsevier.com/locate/jcfJournal of Cystic FibrosisBurkholderia gladioli: Five year experience in a cystic
fibrosis and lung transplantation center☆
Marcus P. Kennedy a,⁎, Raymond D. Coakley b, Scott H. Donaldson b, Robert M. Aris b,
Kathy Hohneker b, Joel P. Wedd c, Michael R. Knowles b,
Peter H. Gilligan c, James R. Yankaskas b
a Department of Pulmonary Medicine, Unit 403, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
b Department of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7030, USA
c Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7030, USA
Received 26 August 2006; received in revised form 12 October 2006; accepted 19 October 2006
Available online 29 November 2006Abstract
Background: The impact of infection with Burkholderia gladioli in cystic fibrosis, other chronic airway diseases and immunosuppressed
patients is unknown.
Methods: A six-year retrospective review of all patients with B. gladioli infection was performed in a tertiary referral center with cystic
fibrosis and lung transplantation programs. In addition, a targeted survey of all 251 lung transplant recipients was performed. Available
B. gladioli isolates were analyzed via pulsed field gel electrophoresis.
Results: Thirty-five patients were culture positive for B. gladioli, including 33 CF patients. No bacteremia was identified. Isolates were
available in 18 patients and all were genetically distinct. Two-thirds of these isolates were susceptible to usual anti-pseudomonal antibiotics.
After acquisition, only 40% of CF patients were chronically infected (≥2 positive cultures separated by at least 6 months). Chronic infection
was associated with resistance to ≥2 antibiotic groups on initial culture and failure of eradication after antibiotic therapy. The impact of
acquisition of B. gladioli infection in chronic infection was variable. Three CF patients with chronic infection underwent lung trans-
plantation. One post-transplant patient developed a B. gladioli mediastinal abscess, which was treated successfully.
Conclusions: The majority of patients' culture positive for B. gladioli at our center have CF. B. gladioli infection is often transient and is
compatible with satisfactory post-lung transplantation outcomes.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Burkholderia gladioli; Lung transplantation; Bronchiectasis1. Introduction
Members of the genus Burkholderia are metabolically
versatile gram-negative organisms occupying diverse eco-
logical niches including soil, plants and human respiratory
tracts. The nomenclature of Burkholderia gladioli, which
is distinct from the Burkholderia cepacia complex, has☆ Supported by NIH-RR00046 and U54RR019480.
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doi:10.1016/j.jcf.2006.10.007evolved from Pseudomonas marginata and Pseudomonas
gladioli to its current designation. It was first recognized as a
plant pathogen of Gladiolus and Iris species [1]. In 1989, B.
gladioli was first described in the medical literature as a
colonizing organism in 11 patients with cystic fibrosis (CF)-
related lung disease (to date, the largest reported series), but
the authors were unable to conclude whether colonization
was associated with adverse outcomes [2]. Since then, case
reports and small case series have highlighted morbidity
associated with B. gladioli in a total of 13 patients. These
included pulmonary disease related to B. gladioli in CFed by Elsevier B.V. All rights reserved.
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chronic granulomatous disease [8,9], and acquired immune
deficiency syndrome [4]. Extra-pulmonary infection has
been identified patients with CF [4–7], in immunocompro-
mised hosts and patients with diabetes mellitus [4,10].
There is a paucity of information in the literature regarding
prevalence of disease associated with B. gladioli in at-risk
patient populations, including patients with CF and other
chronic airway diseases, and patients who are immunosup-
pressed. However, the development of species-specific PCR
testing now permits more accurate microbiological identifi-
cation. This, in turn, creates an opportunity for improved
epidemiological surveillance and more rigorous characteriza-
tion of medical consequences of infection. [11]. In particular,
although previous case reports and case series highlighted
mortality and morbidity associated with B. gladioli infection
after lung transplantation (suggesting infected patients may be
unsuitable candidates for this procedure), these data are
limited by their small sample size.
Because of these considerations, we examined the
prevalence of B. gladioli and its disease associations at our
institution over a six-year period, by performing a compre-
hensive review of all patients' culture positive for B. gladioli
during this time.
2. Methods
2.1. Patients and study design
A retrospective review was performed of all patients who
had one or more positive B. gladioli cultures at UNC
Hospitals between 1999 and 2006 was performed [12].
Patients were identified using an electronic survey of all
microbiology cultures processed at the institution during the
time period. The 1999 time point coincided with theFig. 1. Positive cultures for B. gladioli, 1999–2006. Excludes oneintroduction of a new institutional protocol for definitive
speciation of all (CF and non-CF) Burkholderia isolates at
the Cystic Fibrosis Foundation (CFF)-sponsored B. cepacia
Reference Laboratory and Repository, University of Michi-
gan, Ann Arbor, Michigan [11]. Thus, a careful record of all
Burkholderia organisms, using state of the art culture and
molecular techniques for speciation, was developed and
maintained since this time. Because of the clinical importance
of information pertaining to the course of infected patients
after lung transplantation, a targeted survey of all 251 patients
undergoing lung transplant since the initiation of our program
in 1990 was also performed. This included a manual chart
analysis of all patients transplanted prior to the commence-
ment of electronic surveillance of microbiology results
(1999). Additional patients with a culture yielding B. gladioli
from this search were added to our analysis. Approval for this
study was received from our institutional review board.
All available medical records of all cases that had
confirmed positive cultures for B. gladioli were reviewed.
Data regarding age, sex, ethnicity, comorbidities, pulmonary
function tests (using Knudson %predicted formula), fre-
quency of positive cultures, length of follow-up, sensitivity
testing, other organisms cultured, and evidence of complica-
tions related to B. gladioli including hospital admission and
death were recorded. The diagnosis of cystic fibrosis was
confirmed by clinical phenotype and evidence of confirma-
tory tests (sweat chloride and/or cystic fibrosis transmem-
brane conductance regulator (CFTR) genotype).
2.2. Characterization of cystic fibrosis patients
The UNC Cystic Fibrosis Pulmonary Research and
Treatment Center evaluated 769 CF patients in our pediatric
and adult programs during this time period. A patient with CF
was considered negative for B. gladioli infection if no culturecystic fibrosis that underwent lung transplant prior to 1999.
Table 1
Demographic features, genotype and concomitant positive cultures in 33
cystic fibrosis patients infected with Burkholderia gladioli
Demographic features Total
(n=33) a
Chronic
infection b
(n=12)
Transient
infection
(n=18)
Age (years) at B. gladioli
acquisition (mean ±SD;
range)
15.4±6
(6–33)
n=25
13.5±5
(6–21))
n=7
16±8
(6–33)
n=18
Male sex n (%) 23 (70) 7 (58) 13 (72)
Nonwhite race n (%) 3 (9) 0 (0) 2 (11)
Body mass index at B. gladioli
acquisition (mean±SD)
20±4
n=25
20±2.6
n=7
19.7±5.5
n=18
Diabetes mellitus n (%) 5 (15) 0 (0) 5 (28)
Pancreatic sufficiency n (%) 3 (9) 2 (17) 0 (0)
Δ508/Δ508 homozygote n (%) 19 (58)
n=31
8 (66)
n=11
10 (56)
n=18
FEV1 at B. gladioli acquisition
mean %predicted±SD
(range)
80±30
(11–125)
n=25
82±19
(60–114)
n=7
79±30
(11–125)
n=18
B. gladioli resistance to =2
antibiotic groups n (%)
11 (33) 10 (83) 1 (6)
Other microbes
Staphylococcus aureus n (%) 30 (91) 10 (83) 17 (94)
Pseudomonas aeruginosa n (%) 21 (64) 5 (42) 16 (89)
Burkholderia cepacia complex n (%) 4 (12) 2 (17) 2 (11)
Non-tuberculous mycobacteria n (%) 3 (9) 0 (0) 3 (17)
a Total = includes three CF patients cultured on only one occasion and one
cystic fibrosis who underwent lung transplant prior to 1999.
b Includes three lung transplant recipients.
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commenced in September 1999 (it is our institution's policy to
culture airway secretions from cystic fibrosis patients at least 4
times a year).
CF patients who had positive cultures for B. gladioli were
subdivided into two groups: chronic infection (≥2 positive
cultures separated by at least 6 months) or transient in-
fection (a single positive culture or N1 positive cultures for
B. gladioli separated by less than six subsequent months
and culture negative thereafter). Patients who were labeled
as having chronic infection could have negative cultures
for B. gladioli interspersed with positive cultures.
2.3. Pulmonary function analysis
To assess the impact of B. gladioli infection on pulmonary
function, available spirometric values were reviewed for
5 years before and 5 years after acquisition of the organism in
patients whowere chronically infected. The best FEV1 (forced
expiratory volume in one second) percent predicted for each
quartile during this ten-year period was recorded. For each
patient, the slope of the FEV1 plot before and after acquisition
of B. gladioli was determined by linear regression.
2.4. Microbiological studies
All airway specimens from CF patients are cultured on
MacConkey agar, colistin-nalidixidic acid agar and BCSA
(B. cepacia selective agar) [13]. Antibiotic susceptibility
testing was performed with disc diffusion using Pseudomo-
nas aeruginosa breakpoints [14]. The genotype of available
B. gladioli isolates were analyzed by pulsed field gel
electrophoresis (PFGE), using a protocol previously de-
scribed [13]. Chromosomal digestion was performed using
the restriction endonucleases XbaI and SpeI on all isolates.
Genotype patterns were determined by visual inspection
using standard methodology [15].
3. Results
Thirty-four patients had cultures growing B. gladioli
between September 1999 and March 2006 (Fig. 1). Medical
records were available on all patients, and all patients were
included in this review. Thirty-two patients had CF (92%).
The other two patients included a 28-year-old female with
primary ciliary dyskinesia, who was transiently infected with
B. gladioli, and a 63-year-old female with no prior
pulmonary history who was being mechanically ventilated
for complications of trauma. In both cases, the organism was
pan-susceptible to usual anti-pseudomonal antibiotics tested.
After surveying the medical records of all 251 patients
undergoing lung transplantation at our center, we identified
one additional patient with CF who was culture positive for
B. gladioli prior to September 1999, giving a total of 35
patients in this series. All positive cultures were pulmonary
in origin (sputum, bronchoalveolar lavage or trachealaspirate), and included one intrathoracic lymph node
infection in a patient who underwent lung transplantation
3 months earlier (sampled via transbronchial needle aspirate
and confirmed following surgical debridement). B. gladioli
bacteremia or symptoms of septicemia were not identified.
Yearly incidence rates of new infections did not change over
the five-year time period. We did not identify any apparent
clustering of cases (same clinic day appointment or
simultaneous hospital admission), suggesting that patient-
to-patient transmission was unlikely.
3.1. B. gladioli in cystic fibrosis (n=33)
Between 1999 and 2006, 32 CF patients had positive
sputum cultures for B. gladioli, giving a sputum-positive
prevalence of 4.2% in all of our CF adult and pediatric
populations. This included two patients who subsequently
underwent lung transplantation. As stated earlier, one
additional lung transplant patient had a culture that was
positive for B. gladioli prior to September 1999 and has been
included in the following analyses of 33 CF patients. Table 1
displays demographic features and clinical characteristics of
all CF patients infected with B. gladioli. Four adult patients
had identifiable regular outdoor occupational and/or recrea-
tional exposure (construction work, gardening and cross
country running).
One patient died from respiratory failure while awaiting
lung transplantation 1 year after 2 positive sputum cultures
Fig. 2. Pulse gel electric field analysis of B. gladioli strains recovered from 18 patients. 2a: PFGE gel using the restriction endonuclease Xba1 of B. gladioli
strains recovered from 18 different patients demonstrates 18 different isolates (A–R). 2b: PFGE gel using endonuclease XbaI of sequential isolates (A) of
B. gladioli recovered over a 4 month period from a single cystic fibrosis patient demonstrates that two of the three strains⁎ were identical and all three were
clonal based on having fewer than 4 band differences.
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B. gladioli at time of death. Sixteen percent of all adult
CF patients whose cultures were positive for B. gladioli
were referred for, or had undergone, lung transplantation.
Three patients were only seen once at the CF center and
follow-up cultures were, therefore, available in 30 patients
(Fig. 1). Mean follow up was 8 years (range 2–13). Eighteen
patients (60%) were transiently infected (n=16 with one
positive culture and n=2 with two positive cultures sepa-
rated by less than 3 months) with B. gladioli and 12 patients
(40%) were chronically infected (average number of positive
cultures=11; range 2–25). In 25 patients, clinical and
microbiological data was available prior to acquisition of
B. gladioli (18 transient infection and 7 with chronic infec-
tion). The average number of cultures before and after ac-
quisition of B. gladioli in the transient infection group
(n=18) was 13 (range 1–47) and 10 (range 1–23). Two
patients with transient infection had only one negative cul-
ture available prior to acquisition of B. gladioli and one
patient had only one negative culture available after infection
with B. gladioli. The average number of cultures available
prior to acquisition of B. gladioli in the chronically infected
group (n=7) was 9 (1–17). One patient had only one culture
available prior to chronic infection with B. gladioli. Mean
age was 15.4+6 (6–33) at time of initial positive culture.
Mean FEV1 at time of acquisition of B. gladioli was 82±
19% in the chronically infected group and 79±30% in the
transiently infected group.
The impact of chronic B. gladioli infection on lung
function in the group with clinical and microbiological data
available before and after acquisition of the organism (n=7)
was examined by plotting best FEV1 values during each
quartile for 5 years before and after acquisition and
calculating linear slopes during each period. Because of
the small number of patients in this group and the apparentheterogeneity in lung function trends, statistical testing was
not performed. However, 3 patients appeared to have an
accelerated decline in lung function after B. gladioli
acquisition, whereas the slope of lung function change did
not worsen, or improved, in 4 patients after acquisition.
Documentation of antibiotic therapy directed at B. gladioli
shortly after acquisition was noted for all chronically infected
patients and for 14/18 transiently infected patients (in 4
patients it was uncertain from clinical records whether they
received antibiotic therapy or not). Antibiotic therapies var-
ied in class, route, time and number (one or two antibiotic
classes). Of note, 10/11 initial B. gladioli isolates from those
patients who developed chronic infection were resistant to N2
antibiotic classes, whereas the majority (17/18) of initial
isolates from transiently infected patients were susceptible to
usual anti-pseudomonal antibiotics. Resistance was more
prevalent to 3rd generation cephalosporins (28%) and quino-
lones (20%).
Table 1 highlights concomitant positive cultures for Sta-
phylococcus aureus, P. aeruginosa, B. cepacia complex and
non-tuberculous mycobacteria. There was a high prevalence
(91%) of chronic infection with S. aureus. 7 of 12 (58%)
with chronic B. gladioli infection had no other gram-
negative pathogens isolated after acquisition. In the remain-
ing 5 patients, other gram-negative organisms were less
abundant and infrequently isolated. In contrast, there was a
higher and more typical prevalence (89%) of P. aeruginosa
in the group transiently infected with B. gladioli.
B. cepacia complex species were identified in 4 patients
(3 with B. cenocepacia (Genomovars III); and one with B.
multivorans (Genomovars II)). In 3 patients, the organism
was identified once prior to B. gladioli and therefore did not
persist. One of these patients was subsequently chronically
infected with B. gladioli. In the other patient, continuous
growth of B. gladioli was replaced by B. cenocepacia.
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Three lung transplant recipients were infected with
B. gladioli (one prior to September 1999). The average
age at transplant was 39 years. The culture positive preva-
lence of B. gladioli in our lung transplant population was
1.2%. All lung transplant recipients infected with this
organism had continuously positive cultures before lung
transplantation and at least one positive culture afterward.
The two patients transplanted since 1999 were treated with
intravenous antibiotic therapy directed against B. gladioli
for 3 months after transplantation, in compliance with our
institution's protocol for patients infected with other Bur-
kholderia species. All patients were treated with standard
immunosuppressant regimens, including prednisone, cy-
closporine, and azathioprine. One patient, now 11 years
post-transplant was culture positive for B. gladioli for the
first month post transplant, but BAL cultures have been
negative since. Respiratory specimens from the second
patient grew B. gladioli (as the predominant gram-negative
organism) for at least 7 years pre-transplant. The patient is
now 3 years post-transplant with recurrence of infection
and in-hospital treatment on two occasions. The third
patient, with pre-transplant microbiology predominated by
B. gladioli (resistant to trimethoprim–sulfamethoxazole
and ceftazidime), developed a post-transplant febrile me-
diastinal lymph node infection with abscess formation
3 months post-transplant. Needle aspirate culture was po-
sitive for B. gladioli, which was successfully treated with
combined medical and surgical management. Cultures
were negative for B. gladioli 2 years later.
3.3. Pulsed gel field electrophoresis (n=18)
PGFE was performed on 20 isolates from 18 patients
including 17 CF patients (n=9 continuous (n=2 post-
transplant) and n=8 transient culture positive) and one PCD
patient (Fig. 2a). Strains from each patient were genetically
distinct. One patient had 3 strains available for PGFE
analysis (Fig. 2b). Two of the three strains were identical and
all three were clonal based on having fewer than 4 band
differences.
4. Discussion
We undertook this review of B. gladioli infection, the first
retrospective analysis of the incidence and clinical relevance
of this organism in a large population of at risk patients, to
address the clinical significance of this organism. Advances
in the differentiation of B. gladioli from other Burkholderia
species and other gram-negative organisms over the last
decade present the opportunity for more accurate character-
ization of epidemiology and pathology of B. gladioli
infection. One prior report of six “B. gladioli infected”
cystic fibrosis patients from a single center suggested cross
infectivity in the absence of appropriate infection controlprecautions, but post-publication analysis correctly identi-
fied this isolate as B. cenocepacia [16,17]. Thus, accurate
differentiation from other Burkholderia species now permits
assimilation of more accurate information with important
implications for patient care.
An intrathoracic site characterized the infection in all our
patients with one patient exhibiting a mediastinal lymph
node infection. This is consistent with previous published
literature indicating that the majority of positive cultures are
from the airway [2–10].
An important epidemiological result of this study was that
all isolates available for testing were genotypically distinct.
These results suggest no incidents of cross infection or
geographical clustering in our cohort. This is consistent with
our experience with a larger cohort of CF patient infected with
B. multivorans where evidence for person-to-person spread
based on the presence of the same genotype was unusual [14].
These data indicate that environmental acquisition rather than
person-to-person spread is typical for these two organisms. In
contrast, person-to-person spread is well documented for two
other members of the B. cepacia complex in the absence of
appropriate infection control precautions, B. cenocepacia and
B. dolosa (Genomovars VI) [18,19].
Although two patients did not have CF, all patients had an
identifiable co-morbid condition that plausibly predisposed
them to B. gladioli infection. CFTR mutation distribution in
the CF patients was in proportion with expected distribution
for our predominately Caucasian population [20]. In the
prior published case reports and series [2–10], 17/24 patients
(71%) had cystic fibrosis. The fact that the majority of
patients testing positive for B. gladioli at our center had CF
likely reflects our active cystic fibrosis and lung transplant
programs and special culture techniques used to culture and
identify this organism. There is no national CFF data for this
organism. We have not identified any prior estimate of the
prevalence of B. gladioli in cystic fibrosis in the literature,
although one publication, reporting on the incidence of
Burkholderia strain replacement in 379 patients recovered
from 112 CF treatment centers, suggested a sputum positive
prevalence of approximately 10:1 for B. cepacia complex
species relative to B. gladioli in CF [21].
Increased morbidity and mortality have clearly been
associated with B. cepacia complex (especially B. cenoce-
pacia) [17,21,22] and B. dolosa [19] infections in CF.
Further, epidemic spread, incidents of bacteremia and sepsis,
and poorer lung transplant outcomes are associated with
these organisms [18,19,22–31]. However, the impact of B.
gladioli on CF outcomes is less clear [2–7]. Our results
suggest significantly different outcomes with B. gladioli,
especially when contrasted against B. cenocepacia. First, the
majority of patients who contract B. gladioli manifest
transient infection, which in our case was associated with
the use of antibiotics against isolates that were not as
antibiotic resistant based on in vitro susceptibility results.
Second, bacteremia, or a “cepacia-like syndrome”, was not
identified in our cohort, although B. gladioli bacteremia and
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been highlighted in prior CF patients pre and post-transplant
[4–6].
We approached the important question of whether culture
positivity for B gladioli results in more severe pulmonary
disease in CF by analyzing lung function (FEV1) trends before
and after acquisition of the organism. However, because of the
small size of this group with adequate clinical and microbi-
ologic data, we are unable tomake any firm conclusions. Some
patients appeared to deteriorate from a pulmonary perspective
afterB. gladioli infection, including three patients in whom the
predominant gram-negative organismwas B. gladioli and who
required lung transplantation. Continued observation of this
cohort of patients may in time clarify morbidity and mortality
related to B. gladioli infection.
Our analyses suggest that chronic B. gladioli infection is
associated with lower rates of chronic P. aeruginosa infection
suggesting that B. gladioli is capable of becoming the predo-
minant gram-negative pathogen. In contrast to P. aeruginosa,
chronic infection with S. aureus (91%) was higher than
expected (18–26% in CF adults, 30% in all CF patients
[22,32]). It will be interesting to determine whether the strong
association between B. gladioli and S. aureus infection that we
observed is validated by review of new cases and data from
other CF centers. If real, it may provide insights into the
biology of bacterial communities in the CF lung.
Pan-susceptibility to usual anti-pseudomonal antibiotics in
two thirds of isolates is also in contrast with prior B. gladioli
[7–9] case reports and series, nor is it consistent with the
B. cepacia complex literature (invariably aminoglycoside
resistant) [7,22,24,26]. However, resistance to 2 or more
antibiotic families was identified in patients who were
continuously culture positive patients (10/11) and in those
who ultimately required lung transplantation (3/3), suggesting
that antibiotic resistance is associated with chronic infection.
The published opinions regarding appropriateness of lung
transplantation in CF patients colonized with B. gladioli are
mixed [7,33]. The importance of accurate speciation of
Burkholderia isolates is vital with regard to transplantation,
since many centers do not offer the procedure to patients
with Burkholderia species. We identified a prevalence of
1.2% in our pre-transplant population. Although one patient
developed mediastinal infection, requiring surgical debride-
ment and prolonged antibiotic therapy, he ultimately had a
favorable clinical course. On review of prior case reports and
case series, we identified 4 lung transplant patients with
cystic fibrosis and B. gladioli infection. One patient with
disseminated disease prior to transplant, involving multiple
subcutaneous abscesses, died in the peri-transplant period
[5]. Another patient developed pulmonary, pleural space and
chest wall infection and died 6 months post transplant due to
lung rejection [6], while the remaining two patients
developed post transplant wound infections which were
successfully treated medically [7]. On balance, therefore, we
feel that pre-transplant infection with B. gladioli should not
contraindicate lung transplantation in CF. However; wesuggest that caution is warranted, comorbid status should be
carefully assessed and close follow-up performed with
awareness of chest wall, pleural space and mediastinal
infection. The use of prolonged postoperative intravenous
antibiotic therapy may be beneficial, given the relatively
benign course in 2 of our 3 patients.
In summary, with advancements in microbiological
testing, we have an opportunity to accurately define disease
related to individualBurkholderia species includingB. gladioli.
In this retrospective chart review, we have identified that
the predominant source of B. gladioli isolates in our insti-
tution are from CF patient pulmonary secretions. Impor-
tantly, in our patient population there have been no episodes
of spread between patients, based on PFGE results. Further,
in contrast to B. cenocepacia and B. dolosa, infection may
be transient, especially when an antibiotic susceptible strain
is isolated. However, antibiotic resistant strains did tend to
be chronic, with 3 patients ultimately requiring lung trans-
plantation. We do not feel that infection with B. gladioli is
a contraindication to lung transplantation but feel caution
is warranted and close observation is advised. The ability
to accurately identify and follow this cohort over a pro-
longed time-period offers the opportunity to further inves-
tigate the impact of B. gladioli on pulmonary disease in
cystic fibrosis.
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